1. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126
2. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. https://doi.org/10.1056/NEJMoa2026982
3. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. https://doi.org/10.1056/NEJMoa1816047
4. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. https://doi.org/10.1056/NEJMoa2035716
5. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. https://doi.org/10.1056/NEJMoa1816714
6. Zarbin M. Real life outcomes vs. clinical trial results. J Ophthalmic Vis Res. 2019;14(1):88–92. https://doi.org/10.4103/jovr.jovr_279_18
7. Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18(1):122. https://doi.org/10.1186/s13063-017-1870-2
8. Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: Analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745–52. https://doi.org/10.1200/JCO.2017.73.4186
9. Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, et al. Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO–Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021;27(9):2394–9. https://doi.org/10.1158/1078-0432.CCR-20-3852
10. FDA. Cancer clinical trial eligibility criteria: Patients with HIV, hepatitis B virus, or hepatitis C virus infections [Internet]. FDA; 2020 [cited 2024 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus
11. FDA. Cancer clinical trial eligibility criteria: Brain metastases [Internet]. FDA; 2020 [cited 2024 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-brain-metastases
12. FDA. Cancer clinical trial eligibility criteria: Patients with organ dysfunction or prior or concurrent malignancies [Internet]. FDA; 2020 [cited 2024 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent
13. FDA. Cancer clinical trial eligibility criteria: Performance status [Internet]. FDA; 2024 [cited 2024 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-performance-status
14. FDA. Cancer clinical trial eligibility criteria: Washout periods and concomitant medications [Internet]. FDA; 2024 [cited 2024 May 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications